66900-71-8

Basic information

• Product Name: azanide, cyclohexanamine, platinum(+4) cation, trisulfate
• Synonyms: 1,2-Cyclohexanediamine, (1S-trans)-, platinum sulfate complex;Nsc289543;Platinum, (1,2-cyclohexanediamine-N,N')sulfato(2-)-o,o']-, (sp-4-2) (1S-trans)]-
• CAS NO: 66900-71-8
• Molecular Formula: C12H30N4O12Pt2S3
• Molecular Weight: 908.7492
• Mol File: 66900-71-8.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 134.5°Cat760mmHg
• Flash Point: 32.2°C
• Appearance: /
• Density: g/cm³
• Vapor Pressure: 0.46mmHg at 25°C
• CAS DataBase Reference: azanide, cyclohexanamine, platinum(+4) cation, trisulfate(CAS DataBase Reference)
• NIST Chemistry Reference: azanide, cyclohexanamine, platinum(+4) cation, trisulfate(66900-71-8)
• EPA Substance Registry System: azanide, cyclohexanamine, platinum(+4) cation, trisulfate(66900-71-8)

Safety Data

• Hazardous Substances Data: 66900-71-8(Hazardous Substances Data)

Usage

Description

Azanide, cyclohexanamine, platinum(+4) cation, and trisulfate are chemical compounds with distinct properties and applications. Azanide is a nitrogen-based anion, cyclohexanamine is an organic compound derived from cyclohexane with an amine group, the platinum(+4) cation is a high oxidation state of the platinum element, and trisulfate is a polyatomic anion containing three sulfate groups.

Uses

Used in Pharmaceutical Industry:
Azanide, cyclohexanamine, platinum(+4) cation, and trisulfate are used as active pharmaceutical ingredients for the development of anti-tumor agents. Specifically, (SP-4-2)-[(1S,2S)-1,2-Cyclohexanediamine-κN1,κN2][sulfato(2-)-κO,κO'']platinum is a compound that targets GLUT-mediated transport, making it a potential candidate for the treatment of cancer.
The unique properties of these compounds allow them to interact with biological systems in various ways, making them valuable in the development of new drugs and therapies for cancer treatment. Their specific mechanisms of action and targeting capabilities can contribute to the advancement of cancer research and the improvement of patient outcomes.

InChI:InChI=1/C6H12N2.H2O4S.Pt/c7-5-3-1-2-4-6(5)8;1-5(2,3)4;/h5-8H,1-4H2;(H2,1,2,3,4);/q-2;;+2

Upstream product

• 61848-66-6 cis-dichloro-(cis-1,2-diaminocyclohexane)platinum(II) 
• 66845-32-7 trans-cyclohexamethylene diaminediiodoplatinum(II) 
• 38780-40-4 {(1R,2R)-cyclohexane-1,2-diamine}dichloridoplatinum(II) 

Downstream Products

• 99144-84-0 ((C₆H₁₁)CH₂COO)2Pt(NH₂(C₆H₁₀)NH₂) 
• 96322-13-3 bis(cyclohexanecarboxylato)(1,2-diaminocyclohexane)platinum(II) 
• 96322-20-2 ((CH₂)4CHCCOO)2Pt(NH₂(C₆H₁₀)NH₂) 

Relevant articles and documents

Metal-polysaccharide conjugates: compositions, synthesis and methods for cancer therapy

The current disclosure, in one embodiment, includes a polysaccharide conjugate. This conjugate has a polysaccharide and at least one monomeric amino acid having an O-group covalently bound to the polysaccharide. The conjugate also has at least one metal conjugated by the O-group of the amino acid. According to another embodiment, the disclosure provides a method of synthesizing a polysaccharide conjugate by covalently bonding a monomeric amino acid having an O-group to a polysaccharide and by conjugating a metal to the O-group to form a polysaccharide conjugate. According to a third embodiment, the disclosure relates to a method of killing a cancer cell by administering to the cell an effective amount of a polysaccharide conjugate. This conjugate has a polysaccharide and at least one monomeric amino acid having an O-group covalently bound to the polysaccharide. The conjugate also has at least one metal conjugated by the O-group of the amino acid.